Clinical meaning
the clinician provides advanced palliative care through expert pain and symptom management, applying equianalgesic dosing principles and opioid rotation pharmacology. The WHO analgesic ladder guides escalation from non-opioid analgesics (acetaminophen, NSAIDs) to weak opioids (codeine, tramadol) to strong opioids (morphine, hydromorphone, fentanyl, oxycodone). Equianalgesic conversion uses standardized tables: oral morphine 30 mg equals oral hydromorphone 6 mg equals oral oxycodone 20 mg equals IV morphine 10 mg equals fentanyl transdermal 12 mcg/hr. Opioid rotation is indicated for inadequate analgesia despite dose escalation, intolerable adverse effects, or change in clinical status/administration route; the clinician calculates the equianalgesic dose, applies a 25-50% dose reduction for incomplete cross-tolerance (except methadone which requires greater reduction due to its unique pharmacology including NMDA receptor antagonism and long, variable half-life), and titrates to effect. Breakthrough dosing is calculated at 10-15% of the total 24-hour opioid dose, available every 1-2 hours as needed. The clinician manages opioid adverse effects prophylactically: constipation (stimulant laxative initiated with opioid, not expected to develop tolerance), nausea (usually transient, metoclopramide or haloperidol), sedation (usually transient, consider dose adjustment or psychostimulant), and monitors for respiratory depression. Additional palliative management includes neuropathic pain adjuvants, dyspnea management with low-dose opioids, delirium management, and medical assistance in dying assessments per Canadian legislation.